Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23326692 | 0.92 | L3MBTL1 (0.47) | L3MBTL1POLBALDH1A1NPC1APP | |
| Trifluoroacetic Acid SCHEMBL23326865 | 0.81 | L3MBTL1 (0.43) | L3MBTL1POLBALDH1A1NPC1APP | |
| SCHEMBL23326579 | 0.77 | GLA (0.46) | L3MBTL1POLBALDH1A1NPC1APP | |
| SCHEMBL19126510 | 0.76 | PSMD10 (0.55) | L3MBTL1POLBNPC1APPNOTUM | |
| Trifluoroacetic Acid SCHEMBL30801352 | 0.76 | MIF (0.45) | L3MBTL1POLBALDH1A1NPC1APP | |
| SCHEMBL21990759 | 0.73 | PKM (0.75) | ALDH1A1NPC1PKM | |
| SCHEMBL12571591 | 0.72 | CA12 (0.66) | L3MBTL1POLBNPC1NOTUM | |
| SCHEMBL16991673 | 0.72 | PSMD10 (0.53) | L3MBTL1POLBALDH1A1NPC1APP | |
| SCHEMBL23326705 | 0.70 | MAOA (0.43) | L3MBTL1POLBALDH1A1NPC1APP | |
| SCHEMBL31434856 | 0.69 | NPC1 (0.73) | L3MBTL1POLBALDH1A1NPC1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11885818-B2 | Reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11885818-B2 | Reagent for mass spectrometry | SRMS, PTMS, MMAB | L3MBTL1 2526/4885POLB 3320/4885ALDH1A1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.